Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.53 |
| ▸ | FEN1 | P39748 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15979733 | 0.90 | CES2 (0.62) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL633349 | 0.82 | ERCC5 (0.55) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL10576213 | 0.82 | ERCC5 (0.59) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL2519308 | 0.82 | ERCC5 (0.65) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL10792392 | 0.81 | ERCC5 (0.53) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL15979727 | 0.81 | NR4A2 (0.59) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL4773476 | 0.81 | ERCC5 (0.53) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL30098821 | 0.81 | ERCC5 (0.53) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL30955358 | 0.80 | ERCC5 (0.53) | ERCC5FEN1CES2CES1ALDH1A1 | |
| SCHEMBL20945673 | 0.80 | ERCC5 (0.53) | ERCC5FEN1CES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491721-B2 | N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide; tuberculosis including multi-drug resistant and/or latent tuberculosis; antitubercular drugs | LUPIN LIMITED (IN) | 2009-02-17 | — | — | US | disclosed |
| EP-1750765-B1 | ANTIMYCOBACTERIAL PHARMACEUTICAL COMPOSITION COMPRISING AN ANTITUBERCULAR DRUG | LUPIN LTD (IN) | 2007-09-19 | — | — | EP | disclosed |
| EP-1750765-A2 | ANTIMYCOBACTERIAL PHARMACEUTICAL COMPOSITION COMPRISING AN ANTITUBERCULAR DRUG | Lupin Limited (IN) | 2007-02-14 | — | — | EP | disclosed |
| US-20050256128-A1 | Antimycobacterial pharmaceutical composition | LUPIN LTD | 2005-11-17 | — | — | US | disclosed |
| WO-2005107809-A2 | ANTIMYCOBACTERIAL PHARMACEUTICAL COMPOSITION COMPRISING AN ANTITUBERCULAR DRUG | LUPIN LIMITED (IN) | 2005-11-17 | — | — | WO | disclosed |
| EP-1546097-A1 | PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS | Lupin Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| US-20050107370-A1 | Pyrrole derivatives as antimycobacterial compounds | LUPIN LIMITED (IN) | 2005-05-19 | — | — | US | disclosed |
| WO-2004026828-A1 | PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS | LUPIN LIMITED (IN) | 2004-04-01 | — | — | WO | disclosed |
| US-4035395-A | Process for the preparation of ketones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256128-A1 | Antimycobacterial pharmaceutical composition | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TPMT, PHOSPHO1 | ERCC5 3700/4885FEN1 4011/4885CES2 1754/4885 |
| US-20050107370-A1 | Pyrrole derivatives as antimycobacterial compounds | PGLS, SDHA, SDHB | ERCC5 2950/4885FEN1 2592/4885CES2 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.